The landscape for contract biologics manufacturing is rapidly evolving, with geopolitical tensions, drastic impacts from mergers and acquisitions (M&A), and an increase in research and development (R&D) programs. Contract development and manufacturing organizations (CDMO) have a unique vantage point to view the industry from. In this webcast, biopharma industry veteran Joe Payne, President & COO of Scorpius BioManufacturing, explains his take on the industry.
Key Takeaways:
What considerations companies need to make when selecting U.S. vs overseas manufacturing partners
Why Scorpius went 100% single-use in their newest manufacturing facility
What the market for small-volume, early-stage large molecule programs looks like in the next five years.
Listen to the full webcast on-demand: "The Rapidly Evolving Landscape of Contract Biologics Manufacturing"